BRAF and neoplasm: Tumor responses were demonstrated across the three response assessment criteria (RANO-HGG, RAPNO and RANO-LGG), BRAF alteration type (mutation versus fusion) and prior MAPKi use, including patients who progressed on a MAPKi as their most recent prior therapy.